University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.

The Chalmers University of Technology back pain injection spinout floated in an IPO that was oversubscribed by more than four-fold.

The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.

The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.

Columbia's drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Genomic medicine developer Beam will raise $180m in a upsized initial public offering three years after being spun out of Harvard University.

Chalmers University of Technology-founded baby ventilation monitor developer Monivent will join the Spotlight Stock Market in an IPO where 60% of shares have advance subscriptions in place.

University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.

The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.

Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.